VBY-376

N/A

Report date: 2022/07/19 20:00:45
NME

Base Information

Drug NameVBY-376
Drug Alias NameVBY-376
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionHepatitis C virus serine protease, NS3/NS4A inhibitorsCathepsin B inhibitors
TargetsCathepsin BHepatitis C virus serine protease, NS3/NS4A
Therapy Area/IndicationsHepatitis C, Chronic
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesVirobay Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesVirobay Inc
Active IndicationsN/A
Inactive IndicationsHepatitis C, Chronic

Other Information

ATC CodeN/A
Related LinksN/A